pharmacophore hybridization strategy (Novartis)
90
Structured Review
Novartis
pharmacophore hybridization strategy
Pharmacophore Hybridization Strategy, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pharmacophore+hybridization+strategy/pharmacophore+hybridization+strategy/pm40554983-208-0-5
Average 90 stars, based on 1 article reviews
Pharmacophore Hybridization Strategy, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pharmacophore+hybridization+strategy/pharmacophore+hybridization+strategy/pm40554983-208-0-5
Average 90 stars, based on 1 article reviews
pharmacophore hybridization strategy - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Hybridization:Article Title: Recent advance of KRAS-G12C inhibitors for cancer therapy. Article Snippet: The RAS gene family encodes key oncoproteins that play a central role in cellular signal transduction and tumorigenesis.. KRAS exhibits the highest mutation frequency in human cancers, accounting for approximately 80 % of RAS-driven malignancies, with the glycine-to-cysteine substitution at codon 12 (G12C) being one of the most prevalent oncogenic variants.. RAS proteins regulate downstream signaling pathways by modulating transcription and translation processes, while at the cellular level, they promote malignant phenotypes such as uncontrolled proliferation and metastasis, making them critical therapeutic targets. |